|Bid||3.2200 x 1000|
|Ask||3.2600 x 800|
|Day's Range||3.0800 - 3.3000|
|52 Week Range||1.6200 - 24.0000|
|Beta (3Y Monthly)||6.42|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.33|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 3) Ardelyx Inc (NASDAQ: ARDX ) ( reported positive results ...
Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that Jennifer Sanfilippo has been named interim chief executive officer and director, effective August 28, 2019. Prior to this appointment, Ms. Sanfilippo served as senior vice president and general counsel of Melinta. “Jennifer’s appointment to interim chief executive officer is the result of a thoughtful succession planning process undertaken by the board of directors.
A look at the shareholders of Melinta Therapeutics, Inc. (NASDAQ:MLNT) can tell us which group is most powerful...
Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of -19.46% and 13.96%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced changes to its board of directors and executive management team. David Gill, a current Melinta board member, has been named chairman of the board of directors, effective immediately, succeeding Kevin Ferro, who voluntarily resigned from the position and the board of directors. John H. Johnson voluntarily resigned from his position as chief executive officer (CEO) due to changes in the Company’s circumstances and in order to pursue other opportunities.
~ Revenue of $16.0 million, Including Net Product Sales of $13.8 million, for the Second Quarter 2019 ~ ~ Reduction of Operating Expenses of 32 Percent, or $16.3.
Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that it will report its second quarter 2019 financial results on Friday, August 9, 2019. The Company also announced that it will cancel its 2019 second quarter conference call, which had been previously scheduled for Wednesday, August 7, 2019, at 8:30 a.m. ET. Melinta Therapeutics, Inc. is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions.
Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress when it reports second-quarter results.
Vabomere and Minocin are expected to drive Melinta's (MLNT) second-quarter revenues. Operating expenses are likely to be lower. The company may provide update on progress of Baxdela label expansion.
Melinta Therapeutics, Inc. (MLNT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Melinta Therapeutics, Inc. (MLNT) closed at $4.07 in the latest trading session, marking a -0.49% move from the prior day.
Melinta (MLNT) announces preliminary sales for the second quarter. However, sales number suggests estimates miss for the quarter. Shares fall.
Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today reported preliminary and unaudited financial results and provided a corporate update for the second quarter ended June 30, 2019. “Melinta’s preliminary second quarter 2019 results demonstrate that the actions taken to improve upon the Company's operational and financial efficiencies are continuing to drive progress,” said John H. Johnson, chief executive officer of Melinta.
Given July’s notoriously slow trading environment, I wanted to spend this week’s article breaking down another massively useful trading tool that can signal the trajectory and strength of a stock’s price trend, Volume Weighted Average Price, or VWAP. Like it says on the tin, VWAP is a weighted average of a stock’s trading price that emphasizes price points with the most amount of transactions. VWAP is calculated by taking the average trading price on a single candle and multiplying it by the total number of trades in that candle.
WASHINGTON , July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to ...
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Melinta Therapeutics, Inc. (NASDAQ: MLNT ) ...
64 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 20, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...
Investors need to pay close attention to Melinta Therapeutics (MLNT) stock based on the movements in the options market lately.
Melinta Therapeutics news for Wednesday concerning approval from the U.S. Food and Drug Administration (FDA) has MLNT stock flying high.Source: Shutterstock Melinta Therapeutics (NASDAQ:MLNT) says that it now has approval from the FDA for a supplemental New Drug Application. This supplemental New Drug Application is for expanding the use of the company's BAXDELA drug.BAXDELA is a drug made by Melinta Therapeutics that treats acute bacterial skin and skin structure infections. It first got approval from the FDA in 2017. Now MLNT is seeking to also use the drug to treat adults that are dealing with community-acquired bacterial pneumonia.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSue Cammarata, M.D., Chief Medical Officer of MLNT, has this to say about the Melinta Therapeutics news."Due to the rise of antibiotic resistance and an aging population, community-acquired bacterial pneumonia, or CABP, remains a challenge for healthcare professionals and has led to a need for new treatment options. BAXDELA's potency and activity against the most common bacterial pathogens seen in CABP indicate it could play a significant role in the treatment of this life-threatening illness, if approved. We look forward to working with the FDA to help evaluate bringing this potential option to people with CABP as soon as possible." * 7 Value Stocks to Buy for the Second Half The Melinta Therapeutics news of approval from the FDA gives the supplemental New Drug Application a priority review status. The organization has set a review deadline for the application of Oct. 24, 2019.MLNT stock was up 190% as of Wednesday afternoon. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Value Stocks to Buy for the Second Half * 7 Hot Stocks to Buy for a Seemingly Sleepy Summer * 6 Chip Stocks Staring At Big Headwinds in 2019 As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Melinta Therapeutics News: Why MLNT Stock Is Skyrocketing Today appeared first on InvestorPlace.
Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for BAXDELA® (delafloxacin) for priority review. The sNDA filing seeks to expand the current indication for BAXDELA to include adult patients with community-acquired bacterial pneumonia (CABP). The FDA granted priority review status based on the previous Qualified Infectious Disease Product (QIDP) designation, which provides certain incentives for the development of antibacterial and antifungal treatments for serious or life-threatening infections.
As every investor would know, you don't hit a homerun every time you swing. But it should be a priority to avoid...
The DISARM Act of 2019 provides the framework needed to stabilize the antimicrobial ecosystem, spur development of new infection-fighting drugs, and preserve the effectiveness of existing medicines for ...
Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of 14.29% and -16.29%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the New Haven, Connecticut-based company said it had a loss of $2.34. The drugmaker posted revenue of $14.1 million in the period. In the final minutes of trading on Thursday, the ...